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Abstract
Objectives: To identify Magnetic Resonance Imaging (MRI), clinical and demographic biomarkers
predictive of worsening information processing speed (IPS) as measured by Symbol Digit Modalities
Test (SDMT).
Methods: Demographic, clinical data and 1.5 T MRI scans were collected in 76 patients at time of
inclusion, and after 5 and 10 years. Global and tissue-specific volumes were calculated at each time
point. For the primary outcome of analysis, SDMT was used.
Results: Worsening SDMT at 5-year follow-up was predicted by baseline age, Expanded Disability
Status Scale (EDSS), SDMT, whole brain volume (WBV) and T2 lesion volume (LV), explaining 30.2%
of the variance of SDMT. At 10-year follow-up, age, EDSS, grey matter volume (GMV) and T1 LV
explained 39.4% of the variance of SDMT change.
Conclusion: This longitudinal study shows that baseline MRI-markers, demographic and clinical data
can help predict worsening IPS. Identification of patients at risk of IPS decline is of importance as
follow-up, treatment and rehabilitation can be optimized.
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Introduction
Multiple sclerosis (MS) is a chronic inflammatory
and neurodegenerative disease, characterized by
multifocal areas of demyelination and atrophy of
the central nervous system (CNS).1 These patholog-
ical changes are seen both in the white matter (WM),
and the grey matter (GM) of the CNS.2
Cognitive impairment (CI) in MS has been increas-
ingly investigated over the past decades, and is
acknowledged as a major symptom present in a
large proportion of patients, with a prevalence in
the range of 40–70% in cross-sectional MS-popula-
tions.3 CI affects patients in all stages and subtypes
of the disease, even from the prodromal phase4 and
the early stage of clinically isolated syndrome5 to
those living with the disease for several decades.6
The cognitive domains most commonly affected
are information processing speed and episodic
memory,3 yet impairment of any cognitive domain
could be present.7
Previous studies have shown that MS patients with
CI have a lower chance of being employed, are less
likely to engage in social activities and found house-
hold tasks more difficult. They are also more likely
to suffer from psychiatric illness and have lower
quality of life scores.8 MS CI is associated with
physical disability, as measured by the Expanded
Disability Status Scale (EDSS),9 and predicts later
EDSS worsening.10
MRI biomarkers associated with CI have been
extensively investigated over the past decades.11
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The search for reliable radiological biomarkers has
yielded numerous studies shedding light on the asso-
ciation between lesion volume (LV), atrophy and
CI.12–14 Cerebral atrophy, T2 LV and cortical lesions
have been identified as possible culprits, all of which
result in an increased risk of CI.15–17
Neuropsychological test batteries for investigating
CI in MS are numerous. However, the Symbol
Digit Modalities Test (SDMT) is one of the most
commonly used tests for assessing information proc-
essing speed (IPS), an essential cognitive function.
When IPS is affected, downstream processes may be
influenced, such as memory, executive functions,
learning and word retrieval.18 SDMT is increasingly
attractive for use in the clinical setting as well as
research due to its fast and easy administration,
excellent test-retest reliability, good validity and
high sensitivity to CI in MS.18 A clinical meaningful
change of SDMT has been proposed in several stud-
ies, with a raw score change of 4 points or a 10%
change to be suggestive of cognitive decline.18,19
Our aim is to reveal clinical, demographic and
MRI measures predictive of worsening IPS as
measured by change in SDMT. We also aimed to
explore parameters predictive of a clinically mean-
ingful change of SDMT. Our hypothesis was that




In the years of 1998–2000 patients diagnosed with
multiple sclerosis at the Haukeland University
Hospital (HUS) and Stavanger University Hospital
(SUS) in the south-western parts of Norway were
given the opportunity to enter into the study.
Patients were included at time of diagnosis, and re-
examined after 5- and 10-years. The current diagnos-
tic criteria at the time of enrolment, the criteria of
Poser, were used to establish the diagnosis of MS.20
A total of 108 patients qualified for inclusion. From
those, three patients had moved out of the area, one
was deceased and 11 declined participation, leaving
93 patients. Neurological examination, MRI of the
brain and the required tests were performed in 76 of
these patients, and they were subsequently included
in the present study. The cohort comprised of
patients with all MS-subtypes.
After 5- and 10 years the patients were re-examined,
including MRI of the brain, clinical and cognitive
assessment.
Physical disability was assessed using the EDSS at
each visit.
Level of education at baseline was registered. The
patients were classified as having low (12 years or
less; primary school/junior high), or high (more than
12 years; college/university) level of education.
The regional committee for medical and health
research of western Norway, the Norwegian Centre
for Research Data and the Norwegian Data
Protection Authority approved the study. All patients
signed an informed written consent in accordance
with the Helsinki convention.
MRI acquisition and analysis
The MRI scans were completed at two different
scanners, one located at HUS (Siemens
Symphony), and one at the SUS (Phillips Medical
systems, Intera). The same standardized study pro-
tocol was used at each time-point. The scanner
strength was 1.5 T and the protocol used consisted
of a dual spin echo (SE) proton density (PD)/T2–
weighted image (WI), a three-dimensional (3D)
T1-WI and a SE-T1-WI. The voxel size for (SE)
PD/T2-WI was 0.9 0.9 5.0mm3, for 3D T1-WI
0.9 0.9 1.4mm3, and for SE T1 0.9 0.9
5.0mm3 on the Siemens scanner. On the Philips
scanner the voxel size for (SE) PD/T2-WI was
0.89 0.89 5.0mm3, for 3D T1-WI 0.89 0.89
1.2mm3, and for SE T1 0.89 0.89 5.0mm3.
The protocol is described in detail elsewhere.21
In order to calculate global and tissue-specific atro-
phy measures and lesion volumes, the MRI scans
were subsequently analyzed. Using the FMRIB’s
FLIRT (Functional MRI of the Brain’s Linear
Image Registration Tool), all baseline and follow-
up scans for each subject were co-registered to its
baseline T1 SE image. Next, using the co-registered
images, T1 and T2 lesion volumes (LVs) were cal-
culated using a reliable, semi-automated edge detec-
tion contouring/thresholding technique previously
described.22 Prior to performing further analysis on
the 3D-T1 scans, the lesion-filling tool from FSL
was applied to minimize the impact of WM lesions
on tissue segmentations.23 Normalised measures for
whole brain volume (WBV), GM, WM, cortical
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were measured using SIENAX (V2.6) as previously
described.24,25
From the inpainted 3D-T1 images, absolute volumes
of the subcortical deep grey matter (SDGM) struc-
tures were calculated using the FMRIB’s Integrated
Registration and Segmentation Tool (FIRST V1.2), a
model-based segmentation and registration tool.26
Normalised SDGM volumes were estimated by mul-
tiplying the estimated volumes from FIRST by the
volumetric scaling factor from SIENAX.24
This process is described in detail elsewhere.21
Cognitive evaluation
In order to define CI and cognitively preserved (CP)
at each time point, the patients underwent neuropsy-
chological testing as follows:
• Paced Auditory Serial Addition Test (PASAT)
assessing working memory,
• Selective Reminding Test (SRT) measuring
working memory and learning, including sub-
scores of long time storage (LTS) and delayed
recall (DR)
• Symbol Digits Modalities Test (SDMT) measur-
ing cognitive processing speed
We defined CI as scoring below 1.5 standard devia-
tions (SD) compared to a healthy control group on
two or more tests. A control group consisting of 40
persons was recruited from the staff at SUS. When
comparing to the baseline patient group, the control
group were similar in age (42.4; SD 12.6; p¼ 0.77)
and sex (26 female, 56%; p¼ 0.53) More persons in
the control group had higher education compared to
the patient group (68% vs 34%; p¼ 0.001). .
SDMT has become highly recommended as the pri-
mary cognitive test in MS, thus we chose SDMT
score as the cognitive outcome measure in the
regression analyses.18
Statistical analysis
Descriptive statistics were performed using SPSS
V.26 (Armonk, NY, USA: IBM Corp.). Results are
presented as means and SD, medians and interquar-
tile ranges (IQRs) or as counts and percentages for
continuous symmetric, continuous non-symmetric
and categorical data, respectively.
Baseline predictors of change in SDMT during
follow-up were assessed in linear regression
models. Results from univariable and multivariable
models are presented as unstandardized b values with
95% confidence intervals (CI) and p-values from
Wald tests. As a measure of goodness of fit or pre-
dictive power we present R2, and the change in R2
(DR2) as a measure of the improvement of the model
when including a predictor. Due to limited sample
sizes, we performed the multivariable modelling step-
wise, i.e. by first finding an optimal set of clinical and
demographic variables with high predictive power
(using manual backwards elimination and subsequent
forward inclusion; model fit evaluated by the adjusted
R2), and this model acted as a base model for which
we evaluated added predictive value from each MRI
variable. Finally, the MRI variables that were most
predictive were tried in combination, and a “best”
model decided upon by adjusted R2 (always keeping
the demographic and clinical variables in the model).
Similarly, predictors of clinically meaningful change
in SDMT (i.e. >4 points reduction) were evaluated in
logistic regression models, from which we report
odds ratios (OR) with 95% CI, p-values from Wald
tests, and with Nagelkerke pseudo R2 and the C-index
as measures of predictive performance.
All regression analyses were performed in Stata v. 16.1
with functions regress, logit, roctab and fitstat. P-
values <0.05 were considered statistically significant.
Results
Demographic, clinical and MRI data at baseline, 5-
and 10- year follow up
Baseline demographic, clinical and MRI character-
istics categorized by cognitive status, of the patient
groups at baseline, 5- and 10-year follow-up are
shown in Table 1. At baseline 37 of 76 (49%) of
the patients were classified as cognitively impaired.
The number at 5-year follow up was 28 of 60 (47%)
and at the 10-year follow-up 14 of 38 (37%). After
5 years of follow-up, 66 patients were re-examined
while 50 patients remained at the 10-year follow up
(Figure 1). Of the patients classified as CI at baseline
67.5% dropped out during the course of the follow-
up, comparably 51.3% of the patients classified as
(CP) dropped out during the follow-up.
Clinical and demographic characteristics of the
patient group classified as CI at baseline included
older age, higher EDSS score, longer disease dura-
tion, lower education and lower SDMT score at
baseline compared with the CP group. At 5-year
follow-up the CI patient group were significantly
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At baseline and 5-year follow up, the CI group had
significantly higher T1 and T2 LV, and lower corti-
cal and SDGM volumes.
When comparing the two patient groups followed at
SUS and HUS, we found no significant differences
in clinical, demographic or MRI-parameters between
the groups. For the patients included at HUS,
although not significantly, a longer baseline disease
duration of median 60months (IQR 48–180), com-
pared to SUS patients with a disease duration of
median 48months (IQR 36–84), (p¼ 0.07). Use of
disease modifying therapy (DMT) at 5-year follow-
up were median 2.3months (IQR 0 – 62) at HUS,
and 0 (IQR 0–9.9, p¼ 0.1) at SUS. At 5-year follow-
up 21 of 40 (52.5%) of HUS patients, and 13 of 31
(41.9%) of SUS patients received DMTs. There was
a greater dropout of patients at SUS 19 of 32 (59%)
vs HUS 19 of 44 (43%).
Baseline MRI and clinical variables predicting
change of SDMT
Univariable linear regression analysis showed signif-
icant associations between baseline WBV, GMV,
WMV, CV and T2 LV and change in SDMT
during 5-year follow-up from baseline, where
lower brain volume and higher LV predicted reduc-
tion of SDMT. Of the clinical and demographic var-
iables, we found the combination of age, baseline
EDSS and SDMT to explain 12.6% of the variance
of change in SDMT. Being older, and having a
higher EDSS and SDMT score was associated with
a greater negative SDMT change. When adding indi-
vidual MRI-parameters, WBV, WMV, LVV, T2 and
T1 LV contributed significantly to this model. When
trying combinations of WBV, LVV, T2 and T1 LV
together with the selected clinical and demographi-
cal variables, the best model included baseline WBV
and T2 LV and explained 30.2% of the variation in
SDMT change. Being older and having a lower
EDSS score was associated with a greater negative
SDMT change (Table 2).
Similar analysis was done during the 10-year follow-
up. The univariable linear regression analysis showed
a lower WBV, GMV, CV, SDGM volume, and higher
T1 and T2 LV to be significantly predictive of SDMT
reduction during 10-year follow-up. Age, center and
baseline EDSS together explained 6.2% of the vari-
ance in SDMT change. Out of GMV, CV, T2 and T1
LV, the combination of T1 LV and GMV explained
the most of the variance together with the clinical/
demographical variables, which explained 39.4% of
the SDMT change variance (Table 3).
We explored the effects of DMT, by adding DMT
use at each timepoint dichotomized to active- and
highly-active treatment. When adding DMT to the
model, SDGM volumes were no longer significantly
predictive of SDMT change at 10-year follow-up.
No changes to the 5-year results was seen.
Baseline MRI and clinical variables as predictors of
clinically meaningful change of SDMT
Baseline EDSS, WBV, GMV, WMV, CV, T1 and
T2 LV were significantly predictive of a clinically
meaningful SDMT change of 4 points during 5-year
follow-up in univariable logistic regression analysis.
T2 LV contributed the most to the prediction of clin-
ically meaningful SDMT change of more than 4
points, with an increase in Nagelkerke R2 of 6.6
percentage points and in c-index of 0.03 when
included in the model with center, disease duration
and EDSS at baseline (Supplementary Table 1).
Figure 1. Flow chart of patient inclusion at baseline, 5-year and 10-year follow-up.
Jacobsen et al.
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Only univariable logistic regression analysis could
be performed for clinically meaningful SDMT loss
during 10-year follow-up, due to few cases. None of
the clinical or demographic variables were predic-
tive of clinically meaningful SDMT loss, and of the
MRI-parameters T1 and T2 LV were the only statis-
tically significant predictors of clinically meaningful
SDMT loss (Supplementary Table 2).
Discussion
This prospective, longitudinal study of a cohort of
MS patients identified clinical and MRI-markers
predicting worsening IPS, as measured by SDMT.
Nearly 50% of the patient group where classified as
CI at baseline. This finding is in line with current
knowledge, describing a prevalence of CI in MS
ranging from 40% – 70%, depending on the group
of patients studied, and test-strategies.11
As our patient group had a relatively long disease
duration at baseline of close to 9 years, we suspect
that effects due to brain atrophy as they relate to
cognitive difficulties may have already ensued.
Supporting this theory, is the fact that there was
not an increase in the rate of CI over the 10-year
follow up. Part of the reason for this, however, is
probably due to drop-outs. Of the baseline CI
Table 2. Prediction of change in SDMT during 5 years from baseline (n¼ 66 all analyses).
Univariable Multivariable
Baseline predictor b (95% CI) p R2(%) b (95% CI) p R2(%) DR2(%)
Best model clin/dem
Age –2.2 (–4.8, 0.4) 0.094 4.3 –1.8 (–4.5, 0.9) 0.20
Sex (female) 1.6 (–3.8, 6.9) 0.56 0.5
Center (SUS) –6.1 (–11.0, –1.3) 0.014 9.0 –6.1 (–10.8, –1.4) 0.011




Log disease duration –1.3 (–4.8, 2.1) 0.43 1.0
MS type progressive –3.8 (–10.1, 2.5) 0.23 2.2
EDSS –1.8 (–3.7, 0.1) 0.057 5.6 –1.8 (–3.9, 0.3) 0.084
SDMT –0.11 (–0.31, 0.08) 0.25 2.0 –0.20 (–0.40, –0.01) 0.043
When added to best model clin/dem
Whole brain 0.043 (0.015, 0.071) 0.003 12.7 0.042 (0.009, 0.076) 0.015 29.0 7.4
Grey matter 0.05 (0.01, 0.10) 0.022 8.0 0.05 (–0.00, 0.11) 0.053 26.4 4.8
White matter 0.08 (0.02, 0.13) 0.007 11.0 0.06 (0.00, 0.13) 0.036 27.1 5.5
Ventricular –0.05 (–0.17, 0.06) 0.36 1.3 –0.17 (–0.31, –0.03) 0.015 29.0 7.4
Cortical 0.07 (0.02, 0.13) 0.007 10.9 0.06 (–0.00, 0.13) 0.065 27.7 6.1
T2 LV –0.22 (–0.42, –0.02) 0.028 7.3 –0.35 (–0.55, –0.16) 0.001 35.7 14.1
T1 LV –0.37 (–0.75, 0.02) 0.060 5.4 –0.51 (–0.91, –0.12) 0.012 29.5 7.9
Subcortical 0.29 (–0.17, 0.75) 0.21 2.5 0.30 (–0.19, 0.80) 0.22 23.5 1.9
Caudate 0.5 (–2.3, 3.2) 0.73 0.2 –0.2 (–3.0, 2.7) 0.91 21.6 0.0
Putamen 1.0 (–1.0, 2.9) 0.33 1.5 1.1 (–1.0, 3.2) 0.29 23.1 1.5
Thalamus 1.2 (–0.2, 2.5) 0.094 4.3 1.2 (–0.3, 2.7) 0.11 24.9 3.3
Pallidus –0.8 (–6.4, 4.8) 0.79 0.1 0.9 (–4.9, 6.6) 0.77 21.7 0.1
Hippocampus 1.4 (–0.9, 3.6) 0.23 2.2 1.5 (–0.8, 3.8) 0.20 23.8 2.2
Amygdala 4.7 (–0.7, 10.1) 0.088 4.5 3.3 (–2.2, 8.9) 0.24 23.4 1.8
MS: multiple sclerosis (progressive¼primary and secondary progressive combined); EDSS: expanded disability status scale; SDMT: symbol
digit modalities test; LV: lesion volume; CI: confidence interval.
Note: Effect estimates from linear regression analysis with change in SDMT as outcome (given as SDMT at 5 years minus SDMT at baseline),
and baseline variables as predictors. A positive b value means that a higher value of the predictor is associated with a higher change value, i.e.
a slower decline of cognitive processing speed. A negative b means that a higher value of the predictor is associated with a greater negative
change of SDMT, i.e. a faster decline of cognitive processing speed. R2 estimates the predictive power of each model, and DR2 the contribution
to the model from each predictor.
Bold values denotes statistical significance at the p< 0.05 level.
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patients 67.5% dropped out in the course of the
follow-up, comparably 51.3% of the CP group
dropped out (Figure 1).
One of the main findings of this study is that the
constellation of age, EDSS, SDMT, WBV and T2
LV explained 30.2% of the variance in change of
SDMT 5years after diagnosis. Age, baseline EDSS,
GMV and T1 LV explained 39.4% of the variance in
10-year SDMT change.
A great body of research is available, describing
MRI-parameters associated with CI. WM lesions
are found to be associated with CI in numerous
studies, and specifically disruption of strategic
WM tracts can cause CI among other clinical symp-
toms.27 However, damage to normal appearing WM
and GM have shown stronger correlations to CI.28
Unfortunately though, we were unable to measure
such damage with the imaging protocol utilized in
this study.
Prediction of CI has been explored in a few studies
showing lesion load, WB atrophy, diffuse brain
damage and central atrophy.17,29 A recent study
including 234 patients found cortical volume loss
as the main driver, along with decreased anterior
thalamic radiation integrity, to be the most
Table 3. Prediction of change in SDMT during 10 years from baseline (n¼ 50 all analyses).
Univariable Multivariable
Baseline predictor b (95% CI) p R2(%) b (95% CI) p R2(%) DR2(%)
Best model clin/dem
Age –1.8 (–4.9, 1.4) 0.27 2.6 –3.0 (–6.4, 0.4) 0.083
Sex (female) 0.6 (–6.0, 7.2) 0.86 0.1




Education (high) 1.7 (–4.5, 7.8) 0.59 0.6
Log disease duration –1.6 (–5.6, 2.3) 0.40 1.5
MS type progressive 0.3 (–7.6, 8.3) 0.93 0.0
EDSS 0.6 (–1.6, 2.8) 0.60 0.6 1.7 (–0.7, 4.0) 0.16
SDMT –0.07 (–0.31, 0.17) 0.56 0.7
When added to best model clin/dem
Whole brain 0.036 (0.002, 0.070) 0.036 8.8 0.035 (–0.001, 0.071) 0.057 25.2 6.3
Grey matter 0.06 (0.01, 0.11) 0.018 11.1 0.08 (0.02, 0.13) 0.007 31.2 12.3
White matter 0.03 (–0.04, 0.10) 0.38 1.6 0.01 (–0.06, 0.08) 0.75 19.1 0.2
Ventricular –0.04 (–0.17, 0.10) 0.58 0.6 –0.10 (–0.24, 0.04) 0.17 22.3 3.4
Cortical 0.08 (0.02, 0.13) 0.011 12.7 0.08 (0.02, 0.15) 0.014 29.2 10.3
T2 LV –0.35 (–0.55, –0.15) 0.001 19.9 –0.42 (–0.60, –0.24) <0.001 45.3 26.4
T1 LV –1.0 (–1.5, –0.5) <0.001 24.6 –1.1 (–1.5, –0.7) <0.001 47.5 28.6
Subcortical 0.53 (0.01, 1.05) 0.045 8.1 0.57 (0.07, 1.07) 0.026 27.5 8.6
Caudate 2.0 (–1.2, 5.1) 0.22 3.1 2.1 (–1.0, 5.2) 0.19 22.0 3.1
Putamen 2.0 (–0.3, 4.3) 0.083 6.1 2.5 (0.4, 4.7) 0.023 27.8 8.9
Thalamus 1.5 (–0.0, 3.1) 0.054 7.5 1.5 (–0.0, 3.0) 0.050 25.6 6.7
Pallidus 3.0 (–3.7, 9.6) 0.38 1.6 5.0 (–1.2, 11.3) 0.11 23.4 4.5
Hippocampus 2.6 (0.1, 5.2) 0.042 8.3 2.6 (0.2, 5.0) 0.033 26.8 7.9
Amygdala 5.0 (–1.5, 11.6) 0.13 4.7 4.1 (–2.1, 10.4) 0.19 22.0 3.1
MS: multiple sclerosis (progressive¼primary and secondary progressive combined); EDSS: expanded disability status scale; SDMT: symbol
digit modalities test; LV: lesion volume; CI: confidence interval.
Note: Effect estimates from linear regression analysis with change in SDMT as outcome (given as SDMT at 10 years minus SDMT at baseline),
and baseline variables as predictors. A positive b value means that a higher value of the predictor is associated with a higher change value, i.e. a
slower decline of cognitive processing speed. A negative b means that a higher value of the predictor is associated with a greater negative
change of SDMT, i.e. a faster decline of cognitive processing speed. R2 estimates the predictive power of each model, and DR2 the contribution
to the model from each predictor.
Bold values denotes statistical significance at the p< 0.05 level.
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significant predictors of cognitive decline30 Our
findings support these studies, in showing both
LVs and atrophy of WBV and GMV leading to
worsening IPS.
Clinical and demographic determinants of CI was in
a large study of 303 MS patients found to include
disease duration, EDSS and vocabulary.31 Another
recent study found age to be the only significant
baseline predictor.30 We found similar results, and
even if there was a significant difference between CI
and CP patients regarding level of education, inter-
estingly no predictive value of education at baseline
was seen. This was in line with Eijlers et al,30 and
may indicate that the protective effect of education,
suggested to contribute to cognitive reserve, was
already exhausted at baseline, as the patients had a
quite long disease duration.
When investigating clinically meaningful SDMT
loss of 4 points, EDSS, WBV, GMV, WMV and
CV were significant, independent baseline predic-
tors. The combination of disease duration, EDSS
and T2 LV were the clinical parameters best predic-
tive of SDMT loss of 4 points at 5-year follow-up.
At the 10-year follow-up, only T1 and T2 lesion
volumes were significantly predictive of SDMT
loss of 4 points. Only 13 patients had a 4 point
decline in SDMT, hence type II error could be the
reason why none of the atrophy measures were sta-
tistically significantly associated.
A strength of this paper, is the fact that the patient
group consist of an unselected cohort of MS patients
followed for 10 years from time of diagnosis. The
patients were mainly untreated for the first part of
the follow-up, providing insight in the occurrence of
brain atrophy and CI in the absence of newer, potent
treatment options.
Some limitations need mentioning. We had a rela-
tively small sample size, and a noticeable drop-out
of (about 35 pts) over the 10-year follow up. The
results of the 10-year follow-up group needs to be
interpreted with care as the patient group is small.
Decrease in SDMT score was used as the primary
outcome. However, some patients had improved
SDMT score over the follow-up. At 5-year follow-
up 26 of the 66 patients had an improved SDMT
score, the total number of patients having an
improved SDMT score at 10-year follow-up was
28 out of 50.
Scans were obtained using 1.5 T MRI systems, vol-
umetric segmentations would have been more pre-
cise and reliable using a 3T MRI. Performing MRI
scans on two different scanners is a possible source
of error, however, effects of different scanners on
longitudinal volume changes are considered to be
minor.32 It is essential to emphasize that this
paper, for the main part, specifically investigated
IPS decline, not CI at a broader level. Cognitive
reserve could have a protective effect on cognitive
decline, unfortunately proper evaluation was not
possible due to lack of information beyond educa-
tion and occupational status.
Our work highlights the current practice, aiming to
diagnose these patients precisely and timely, to be
able to start therapy early, and thus breaking the
vicious circle of lesion formation and brain atrophy.
Cognitive impairment is potentially very detrimental
to MS patients’ level of function and quality of
life.33 Precise clinical and MRI markers helping
clinicians detecting patients at risk of cognitive
decline, would be of great help, as it may aid treat-
ment decisions.
Conclusion
The growing awareness of cognitive difficulties in
MS is essential for the patients and treating physi-
cians, and identifying patients at risk of developing
cognitive difficulties is key. The current study shows
that both clinical and demographic charateristics is
important in predicting ensuing cognitive difficul-
ties, and that MRI parameters add to the explanatory
model. Identifying patients at higher risk of devel-
oping cognitive difficulties could help clinicians ini-
tiate proper follow-up, and treatment decisions.
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